menu
    • menu

    Company profile for Imara

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Imara is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies. Our pipeline is built on the differentiated therapeutic potential of our initial product candidate, IMR-687, which is an oral, once-a-day, highly selective, potent small molecule inhibitor of PDE9 in devel...
    Imara is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies. Our pipeline is built on the differentiated therapeutic potential of our initial product candidate, IMR-687, which is an oral, once-a-day, highly selective, potent small molecule inhibitor of PDE9 in development for sickle cell disease and beta-thalassemia. Sickle cell disease and beta-thalassemia have limited treatment options and are both characterized by severe symptoms and effects and reduced life expectancy.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ImaraUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    116 Huntington Ave., 6th Floor | Boston, MA 02116
    Telephone
    Telephone
    +1 617-206-2020
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://imaratx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Imara Announces Stockholder Approval of Merger With Enliven
    Imara Announces Stockholder Approval of Merger With Enliven

    22 Feb 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/02/22/2613692/0/en/Imara-Announces-Stockholder-Approval-of-Merger-With-Enliven.html

    GLOBENEWSWIRE
    22 Feb 2023
    Share Share
    Enliven to enter public markets through reverse merger with Imara
    Enliven to enter public markets through reverse merger with Imara

    15 Oct 2022

    // Jacob Bell BIOPHARMADIVE

    https://www.biopharmadive.com/news/enliven-imara-reverse-merger-deal-public-market/634151/

    Jacob Bell BIOPHARMADIVE
    15 Oct 2022
    Share Share
    Enliven Therapeutics and Imara Announce Merger Agreement
    Enliven Therapeutics and Imara Announce Merger Agreement

    13 Oct 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/10/13/2534321/0/en/Enliven-Therapeutics-and-Imara-Announce-Merger-Agreement.html

    GLOBENEWSWIRE
    13 Oct 2022
    Share Share
    Imara sells failed blood disorder drug to heart disease outfit Cardurion
    Imara sells failed blood disorder drug to heart disease outfit Cardurion

    10 Sep 2022

    // Lei Lei Wu ENDPTS

    https://endpts.com/imara-sells-failed-blood-disorder-drug-to-heart-disease-outfit-cardurion/

    Lei Lei Wu ENDPTS
    10 Sep 2022
    Share Share
    After Disappointing Data, Imara Offloads It Sickle Cell Candidate, Shares Surge
    After Disappointing Data, Imara Offloads It Sickle Cell Candidate, Shares Surge

    08 Sep 2022

    // Vandana Singh YAHOO

    https://finance.yahoo.com/finance/news/disappointing-data-imara-offloads-sickle-130541406.html

    Vandana Singh YAHOO
    08 Sep 2022
    Share Share
    Imara to reduce staff by 83% amid biotech shakeout
    Imara to reduce staff by 83% amid biotech shakeout

    19 Apr 2022

    // B. Fidler BIOPHARMADIVE

    https://www.biopharmadive.com/news/imara-layoffs-sickle-cell-drug-biotech-downturn/622176/

    B. Fidler BIOPHARMADIVE
    19 Apr 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search